Literature DB >> 25324307

Platinum: a database of experimentally measured effects of mutations on structurally defined protein-ligand complexes.

Douglas E V Pires1, Tom L Blundell2, David B Ascher3.   

Abstract

Drug resistance is a major challenge for the treatment of many diseases and a significant concern throughout the drug development process. The ability to understand and predict the effects of mutations on protein-ligand affinities and their roles in the emergence of resistance would significantly aid treatment and drug design strategies. In order to study and understand the impacts of missense mutations on the interaction of ligands with the proteome, we have developed Platinum (http://structure.bioc.cam.ac.uk/platinum). This manually curated, literature-derived database, comprising over 1000 mutations, associates for the first time experimental information on changes in affinity with three-dimensional structures of protein-ligand complexes. To minimize differences arising from experimental techniques and to directly compare binding affinities, Platinum considers only changes measured by the same group and with the same amino-acid sequence used for structure determination, providing a direct link between protein structure, how a ligand binds and how mutations alter the affinity of the ligand of the protein. We believe Platinum will be an invaluable resource for understanding the effects of mutations that give rise to drug resistance, a major problem emerging in pandemics including those caused by the influenza virus, in infectious diseases such as tuberculosis, in cancer and in many other life-threatening illnesses.
© The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25324307      PMCID: PMC4384026          DOI: 10.1093/nar/gku966

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


INTRODUCTION

Mutations can result in a range of changes to protein function by altering its stability and affinity for binding partners including other proteins and peptides, nucleic acids and small molecules. The strong selective pressure imposed by small molecule drugs on many quickly evolving systems, including viruses, bacteria and human cancer, can lead to the rapid development of resistance (1–4). While rapid and cheaper DNA sequencing has allowed these mutations to be quickly identified in members of large populations (5,6), the significance and characterization of any novel polymorphisms currently requires time-consuming and costly experiments. Ligand-binding affinity data for proteins have been an essential source of information for understanding the effects of polymorphisms in disease (7), in addition to identifying those that result in the development of resistance, an increasingly significant problem (8,9). Efforts to link missense mutations to the development of resistance in specific diseases, for example in cancer, tuberculosis and HIV (10–12), have highlighted the importance of these mutations. However, the understanding of the effects of mutations on ligand binding will help expand our knowledge of mechanisms of action, allowing extrapolations to novel mutations and systems. Awareness of these changes is also an essential step toward more effective, personalized and targeted treatment strategies. For example, the resistance profile of emerging influenza strains has been of significant interest to ensure that appropriate antiviral therapeutics can be rapidly administered in the event of an outbreak (13). Databases that have linked non-synonymous single nucleotide polymorphisms (nsSNPs) with structural information and experimentally measured changes in thermodynamic data (14–16) have enabled the development of computational approaches to evaluate missense mutations (17–19) for their effects on protein stability and binding to protein and nucleic acid partners, expanding our understanding of their roles in disease. Despite its relevance and potential to support studies on emerging phenomena such as drug resistance, no such information is readily available to interrogate the effects of mutations on ligand-binding affinity. A compilation of small molecule structural and affinity data for wild-type and mutant proteins would therefore be a valuable resource for developing methods to elucidate mechanisms behind ligand binding and to predict the effects of mutations. In order to fill this gap, we have designed and implemented a freely accessible database, called Platinum, which compiles and associates small molecule affinity data with structural information, experimental methods and conditions, and ligand properties. Furthermore, we have provided a web interface to facilitate searching the database, sorting, visualizing and downloading the results (http://structure.bioc.cam.ac.uk/platinum).

MATERIALS AND METHODS

Data acquisition and curation

The scientific literature available in PubMed was mined in order to select papers containing structural information of protein–ligand complexes and affinity data for complexes of both wild-type and mutant proteins. An initial pool of papers was compiled for manual inspection by selecting those with mutation information associated with deposited protein–ligand complexes in the RCSB Protein Data Bank (20). In order to do so, paper titles and abstracts were filtered using regular expression matching in order to identify candidates for manual curation. The set of terms used on the regular expressions included root words of ‘mutation’, ‘resistance’ and mutation codes in the format , where WT-Res is the one-letter code for the wild-type, Res-Num is the residue number and MT-Res is the one-letter code for the mutant residue. This procedure identified over 1000 papers, which were manually evaluated against filtering criteria that include requiring affinity data for the construct for which the three-dimensional structure had been determined. To minimize differences arising from experimental techniques and to be able to compare directly binding affinities (21), we considered only affinity changes measured by the same group, using the same technique and conditions, and with the same amino-acid sequence used to determine the three-dimensional structure, providing a direct link between protein structure, how a ligand binds and how mutations alter the affinity of the ligand for the protein. EC50/IC50 measurements in the absence of the Michaelis constant were not considered due to their inherent dependency on experimental conditions, and incompatibility with binding affinities. Only data from techniques that directly measure the ligand affinity to a protein were entered into Platinum, since indirect methods such as cellular assays have many confounding factors and were therefore discarded. Approximately 20% of the identified papers matched our criteria and were manually curated to obtain data that would reflect the effects of mutations on protein–ligand affinity. Over 1000 different affinity data points were manually collated from 182 papers indexed by PubMed. Additional details regarding the experimental techniques and conditions were also entered into Platinum. The PDB-coordinate files for 250 different protein–ligand complexes were downloaded from the RCSB Protein Data Bank, pre-processed and used to supply additional information regarding the protein. In order to account for additional consequences of the mutations, the predicted effects of single point mutations on protein stability in the three-dimensional structure were calculated using the integrated approach DUET (17), when a wild-type PDB structure is available. The effects of the mutations on the affinity of a protein–protein interface were predicted by mCSM-PPI (18) when a single-point mutation was within 5 Å of a biologically relevant interface, as defined by the author-assigned assemblies. Ligand properties such as molecular weight, logP, number of hydrogen acceptors and donors were calculated using RDKit and complementary ligand information such as Canonical Smiles and ligand type were obtained from the PDBeChem (22). All entries were manually double-checked, with additional filters used to confirm the correctness of all structural and affinity information. Figure 1 shows the workflow for data collection and curation used to build Platinum.
Figure 1.

Architecture of data integration and curation of Platinum.

Architecture of data integration and curation of Platinum.

Database architecture and web interface

The collected data were consolidated as a MySQL relational database (version 5.5.35). The information stored in Platinum can be easily queried and downloaded via a user-friendly web interface. Its front-end was implemented using the Bootstrap framework version 2.0, while the back-end was built in Python via the Flask framework (version 0.10.1), running on a Linux server.

RESULTS: DATABASE FEATURES

Web interface

The web interface to the database displays the home page of Platinum. From here users can access the entire database through a ‘Browse’ function or query the database through a ‘Search’ function (Figure 2). For each data point, displayed by default (Supplementary Figure S1 in Supplementary Material) are the protein name, mutation details, whether the mutation is within 5 Å of the ligand-binding site, the ligand ID (as appears in the PDB), the type of affinity measurement, the affinity for the ligand of the reference and mutant proteins (nM), the PDB codes of the reference and/or mutant protein in complex with the ligand and the PubMed ID of the paper where the affinity data were published.
Figure 2.

Platinums web interface search page. It allows users to query the database by combining different searching criteria such as ligand type, organism from which the protein originates and functional classification as well as mutation properties.

Platinums web interface search page. It allows users to query the database by combining different searching criteria such as ligand type, organism from which the protein originates and functional classification as well as mutation properties. Additional information regarding the mutation, protein, ligand and affinity measurements can be toggled on and off depending on requirements of the user. Detailed information of thelocation of the mutation, including secondary structure, hydrogen bonding and solvent accessibility of the reference residue, can be displayed by toggling on residue properties. The extra experimental information includes the method, pH and temperature at which the affinities were measured, as well as the predicted changes in the affinity. The ‘protein toggle’ reveals information about the structure, including the organism, resolution and R-factors. The ‘ligand toggle’ will show several properties calculated using RDKit or obtained from PDBeChem. To facilitate downstream analysis, hyperlinks to the RCSB PDB entries and PubMed abstracts have been included.

Querying the database and downloading the results

The database can be queried using the web interface (Figure 2). This provides the ability to search the database by ligand and protein type, the kingdom of the organism from which the protein originates, the effect of the mutation on the affinity for the ligand, how the affinity was measured and whether only high-resolution structures, KD's or single-point mutations should be displayed. The web interface also provides several methods for exporting data. Firstly, the entire platinum database can be downloaded as a comma-delimited file. All the processed and filtered PDB files linked in Platinum can also be downloaded as a separate file. Secondly, the results retrieved by a query can be exported separately as a comma-delimited file.

Data statistics

Currently Platinum contains more than 1000 unique data points, with 72% of mutations leading to either a significant increase (16%) or decrease (56%) in protein–ligand affinity of over 2-fold (Figure 3A). Most mutations in Platinum (75%) involve residues directly interacting with the ligand in the three-dimensional structure. Approximately 80% of the data points are from single-point mutations, which are more amenable to computational predictions. The information stored in the database represents a diverse range of proteins, ligands and interactions, as summarized in Table 1. The ligands in the database are quite varied, with molecular weights ranging from 90 to 900 Da (Figure 3B) and including fragments, inhibitors and therapeutics as well as natural co-factors and substrates (other properties of ligands in Platinum are also depicted in Supplementary Figure S2 of Supplementary Material). The proteins present in the database represent a wide range of biological activities (Figure 3C) highlighting the broad range of effects encompassed within Platinum. While the proteins are from a diverse selection of organisms, the majority (60%) are from organisms in the Bacterial Domain and Animalia Kingdom (Figure 3D), with approximately 20% of the data from Homo sapiens proteins. This reflects the research emphasis within these areas.
Figure 3.

Platinum entries statistics. In (A), the histogram of the density distribution of the effect of mutations on protein–ligand affinity within Platinum is shown as the fold change (ratio between affinities of reference and mutant). In (B), the histogram of the density distribution of molecular weights of unique ligands in Platinum is shown. The proteins in Platinum are classified by their function, with the proportion of proteins in the most common classes shown in (C). The proteins are also classified phylogenetically in groups and the proportion of data points per class is shown in (D).

Table 1.

Overview of data represented in Platinum

PropertyFrequency
#Mutations1008
#Single-point mutations797
#Papers (by PMID)182
#Unique Uniprots142
#Unique ligands207
#Unique protein-ligand complexes250
#Total unique PDB IDs451
#Affinities given in KD560
Platinum entries statistics. In (A), the histogram of the density distribution of the effect of mutations on protein–ligand affinity within Platinum is shown as the fold change (ratio between affinities of reference and mutant). In (B), the histogram of the density distribution of molecular weights of unique ligands in Platinum is shown. The proteins in Platinum are classified by their function, with the proportion of proteins in the most common classes shown in (C). The proteins are also classified phylogenetically in groups and the proportion of data points per class is shown in (D).

DISCUSSION

The threat of resistance to current therapies is becoming of increasing concern and is widely publicized, especially in regard to the use of antibiotics (23) and emerging pandemics including those caused by the influenza virus (4), in infectious diseases such as tuberculosis (24), in cancer (3) and many other life-threatening illnesses. A repository of mutations and the protein structures within which they occur should be a useful tool to aid the understanding of ligand binding, the development of resistance or the target of a drug or chemical tool. However, no attempt has been made previously to catalog these results, and thus this useful information is currently difficult to access. Previous resources such as PDBbind (25), AffinDB (26) and BindingMOAD (27) provide only the affinity for crystal complexes, while Platinum also maps the effects of mutations on binding affinity. Platinum is also significantly different from BindingDB (28)—only 25% of affinities in Platinum are also present in BindingDB. Platinum is the first comprehensive database of its kind that provides experimental information related to changes in protein–ligand affinities upon mutation and their three-dimensional structures. Besides providing a collection of affinity and structural data, various analyses and links to web-based databases have been integrated into Platinum to facilitate the detailed examination of these mutations. Platinum will also be useful for developing novel in silico predictive approaches. We have observed that predicted changes in protein stability and protein–protein affinity upon mutation show a poor correlation with experimentally measured changes in ligand affinity; therefore a new general method to encompass these effects is required. Some properties appear to correlate better with affinity change, including the distance of the mutated residue to the binding site as well as changes in residue properties. We are currently using structural signatures together with these observations to develop a universal predictive method. The accurate prediction of the changes in ligand affinity upon mutation may not only enhance our understanding of ligand binding and aid in the drug development process but also allow directed administration of therapeutics most likely to be efficacious.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.
  28 in total

1.  Public database for HIV drug resistance in southern Africa.

Authors:  Tulio de Oliveira; Robert W Shafer; Christopher Seebregts
Journal:  Nature       Date:  2010-04-01       Impact factor: 49.962

2.  The PDBbind database: methodologies and updates.

Authors:  Renxiao Wang; Xueliang Fang; Yipin Lu; Chao-Yie Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2005-06-16       Impact factor: 7.446

Review 3.  Application of 'next-generation' sequencing technologies to microbial genetics.

Authors:  Daniel MacLean; Jonathan D G Jones; David J Studholme
Journal:  Nat Rev Microbiol       Date:  2009-04       Impact factor: 60.633

4.  International network of cancer genome projects.

Authors:  Thomas J Hudson; Warwick Anderson; Axel Artez; Anna D Barker; Cindy Bell; Rosa R Bernabé; M K Bhan; Fabien Calvo; Iiro Eerola; Daniela S Gerhard; Alan Guttmacher; Mark Guyer; Fiona M Hemsley; Jennifer L Jennings; David Kerr; Peter Klatt; Patrik Kolar; Jun Kusada; David P Lane; Frank Laplace; Lu Youyong; Gerd Nettekoven; Brad Ozenberger; Jane Peterson; T S Rao; Jacques Remacle; Alan J Schafer; Tatsuhiro Shibata; Michael R Stratton; Joseph G Vockley; Koichi Watanabe; Huanming Yang; Matthew M F Yuen; Bartha M Knoppers; Martin Bobrow; Anne Cambon-Thomsen; Lynn G Dressler; Stephanie O M Dyke; Yann Joly; Kazuto Kato; Karen L Kennedy; Pilar Nicolás; Michael J Parker; Emmanuelle Rial-Sebbag; Carlos M Romeo-Casabona; Kenna M Shaw; Susan Wallace; Georgia L Wiesner; Nikolajs Zeps; Peter Lichter; Andrew V Biankin; Christian Chabannon; Lynda Chin; Bruno Clément; Enrique de Alava; Françoise Degos; Martin L Ferguson; Peter Geary; D Neil Hayes; Thomas J Hudson; Amber L Johns; Arek Kasprzyk; Hidewaki Nakagawa; Robert Penny; Miguel A Piris; Rajiv Sarin; Aldo Scarpa; Tatsuhiro Shibata; Marc van de Vijver; P Andrew Futreal; Hiroyuki Aburatani; Mónica Bayés; David D L Botwell; Peter J Campbell; Xavier Estivill; Daniela S Gerhard; Sean M Grimmond; Ivo Gut; Martin Hirst; Carlos López-Otín; Partha Majumder; Marco Marra; John D McPherson; Hidewaki Nakagawa; Zemin Ning; Xose S Puente; Yijun Ruan; Tatsuhiro Shibata; Michael R Stratton; Hendrik G Stunnenberg; Harold Swerdlow; Victor E Velculescu; Richard K Wilson; Hong H Xue; Liu Yang; Paul T Spellman; Gary D Bader; Paul C Boutros; Peter J Campbell; Paul Flicek; Gad Getz; Roderic Guigó; Guangwu Guo; David Haussler; Simon Heath; Tim J Hubbard; Tao Jiang; Steven M Jones; Qibin Li; Nuria López-Bigas; Ruibang Luo; Lakshmi Muthuswamy; B F Francis Ouellette; John V Pearson; Xose S Puente; Victor Quesada; Benjamin J Raphael; Chris Sander; Tatsuhiro Shibata; Terence P Speed; Lincoln D Stein; Joshua M Stuart; Jon W Teague; Yasushi Totoki; Tatsuhiko Tsunoda; Alfonso Valencia; David A Wheeler; Honglong Wu; Shancen Zhao; Guangyu Zhou; Lincoln D Stein; Roderic Guigó; Tim J Hubbard; Yann Joly; Steven M Jones; Arek Kasprzyk; Mark Lathrop; Nuria López-Bigas; B F Francis Ouellette; Paul T Spellman; Jon W Teague; Gilles Thomas; Alfonso Valencia; Teruhiko Yoshida; Karen L Kennedy; Myles Axton; Stephanie O M Dyke; P Andrew Futreal; Daniela S Gerhard; Chris Gunter; Mark Guyer; Thomas J Hudson; John D McPherson; Linda J Miller; Brad Ozenberger; Kenna M Shaw; Arek Kasprzyk; Lincoln D Stein; Junjun Zhang; Syed A Haider; Jianxin Wang; Christina K Yung; Anthony Cros; Anthony Cross; Yong Liang; Saravanamuttu Gnaneshan; Jonathan Guberman; Jack Hsu; Martin Bobrow; Don R C Chalmers; Karl W Hasel; Yann Joly; Terry S H Kaan; Karen L Kennedy; Bartha M Knoppers; William W Lowrance; Tohru Masui; Pilar Nicolás; Emmanuelle Rial-Sebbag; Laura Lyman Rodriguez; Catherine Vergely; Teruhiko Yoshida; Sean M Grimmond; Andrew V Biankin; David D L Bowtell; Nicole Cloonan; Anna deFazio; James R Eshleman; Dariush Etemadmoghadam; Brooke B Gardiner; Brooke A Gardiner; James G Kench; Aldo Scarpa; Robert L Sutherland; Margaret A Tempero; Nicola J Waddell; Peter J Wilson; John D McPherson; Steve Gallinger; Ming-Sound Tsao; Patricia A Shaw; Gloria M Petersen; Debabrata Mukhopadhyay; Lynda Chin; Ronald A DePinho; Sarah Thayer; Lakshmi Muthuswamy; Kamran Shazand; Timothy Beck; Michelle Sam; Lee Timms; Vanessa Ballin; Youyong Lu; Jiafu Ji; Xiuqing Zhang; Feng Chen; Xueda Hu; Guangyu Zhou; Qi Yang; Geng Tian; Lianhai Zhang; Xiaofang Xing; Xianghong Li; Zhenggang Zhu; Yingyan Yu; Jun Yu; Huanming Yang; Mark Lathrop; Jörg Tost; Paul Brennan; Ivana Holcatova; David Zaridze; Alvis Brazma; Lars Egevard; Egor Prokhortchouk; Rosamonde Elizabeth Banks; Mathias Uhlén; Anne Cambon-Thomsen; Juris Viksna; Fredrik Ponten; Konstantin Skryabin; Michael R Stratton; P Andrew Futreal; Ewan Birney; Ake Borg; Anne-Lise Børresen-Dale; Carlos Caldas; John A Foekens; Sancha Martin; Jorge S Reis-Filho; Andrea L Richardson; Christos Sotiriou; Hendrik G Stunnenberg; Giles Thoms; Marc van de Vijver; Laura van't Veer; Fabien Calvo; Daniel Birnbaum; Hélène Blanche; Pascal Boucher; Sandrine Boyault; Christian Chabannon; Ivo Gut; Jocelyne D Masson-Jacquemier; Mark Lathrop; Iris Pauporté; Xavier Pivot; Anne Vincent-Salomon; Eric Tabone; Charles Theillet; Gilles Thomas; Jörg Tost; Isabelle Treilleux; Fabien Calvo; Paulette Bioulac-Sage; Bruno Clément; Thomas Decaens; Françoise Degos; Dominique Franco; Ivo Gut; Marta Gut; Simon Heath; Mark Lathrop; Didier Samuel; Gilles Thomas; Jessica Zucman-Rossi; Peter Lichter; Roland Eils; Benedikt Brors; Jan O Korbel; Andrey Korshunov; Pablo Landgraf; Hans Lehrach; Stefan Pfister; Bernhard Radlwimmer; Guido Reifenberger; Michael D Taylor; Christof von Kalle; Partha P Majumder; Rajiv Sarin; T S Rao; M K Bhan; Aldo Scarpa; Paolo Pederzoli; Rita A Lawlor; Massimo Delledonne; Alberto Bardelli; Andrew V Biankin; Sean M Grimmond; Thomas Gress; David Klimstra; Giuseppe Zamboni; Tatsuhiro Shibata; Yusuke Nakamura; Hidewaki Nakagawa; Jun Kusada; Tatsuhiko Tsunoda; Satoru Miyano; Hiroyuki Aburatani; Kazuto Kato; Akihiro Fujimoto; Teruhiko Yoshida; Elias Campo; Carlos López-Otín; Xavier Estivill; Roderic Guigó; Silvia de Sanjosé; Miguel A Piris; Emili Montserrat; Marcos González-Díaz; Xose S Puente; Pedro Jares; Alfonso Valencia; Heinz Himmelbauer; Heinz Himmelbaue; Victor Quesada; Silvia Bea; Michael R Stratton; P Andrew Futreal; Peter J Campbell; Anne Vincent-Salomon; Andrea L Richardson; Jorge S Reis-Filho; Marc van de Vijver; Gilles Thomas; Jocelyne D Masson-Jacquemier; Samuel Aparicio; Ake Borg; Anne-Lise Børresen-Dale; Carlos Caldas; John A Foekens; Hendrik G Stunnenberg; Laura van't Veer; Douglas F Easton; Paul T Spellman; Sancha Martin; Anna D Barker; Lynda Chin; Francis S Collins; Carolyn C Compton; Martin L Ferguson; Daniela S Gerhard; Gad Getz; Chris Gunter; Alan Guttmacher; Mark Guyer; D Neil Hayes; Eric S Lander; Brad Ozenberger; Robert Penny; Jane Peterson; Chris Sander; Kenna M Shaw; Terence P Speed; Paul T Spellman; Joseph G Vockley; David A Wheeler; Richard K Wilson; Thomas J Hudson; Lynda Chin; Bartha M Knoppers; Eric S Lander; Peter Lichter; Lincoln D Stein; Michael R Stratton; Warwick Anderson; Anna D Barker; Cindy Bell; Martin Bobrow; Wylie Burke; Francis S Collins; Carolyn C Compton; Ronald A DePinho; Douglas F Easton; P Andrew Futreal; Daniela S Gerhard; Anthony R Green; Mark Guyer; Stanley R Hamilton; Tim J Hubbard; Olli P Kallioniemi; Karen L Kennedy; Timothy J Ley; Edison T Liu; Youyong Lu; Partha Majumder; Marco Marra; Brad Ozenberger; Jane Peterson; Alan J Schafer; Paul T Spellman; Hendrik G Stunnenberg; Brandon J Wainwright; Richard K Wilson; Huanming Yang
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

5.  Rapid pneumococcal evolution in response to clinical interventions.

Authors:  Nicholas J Croucher; Simon R Harris; Christophe Fraser; Michael A Quail; John Burton; Mark van der Linden; Lesley McGee; Anne von Gottberg; Jae Hoon Song; Kwan Soo Ko; Bruno Pichon; Stephen Baker; Christopher M Parry; Lotte M Lambertsen; Dea Shahinas; Dylan R Pillai; Timothy J Mitchell; Gordon Dougan; Alexander Tomasz; Keith P Klugman; Julian Parkhill; William P Hanage; Stephen D Bentley
Journal:  Science       Date:  2011-01-28       Impact factor: 47.728

6.  SDM--a server for predicting effects of mutations on protein stability and malfunction.

Authors:  Catherine L Worth; Robert Preissner; Tom L Blundell
Journal:  Nucleic Acids Res       Date:  2011-05-18       Impact factor: 16.971

7.  ProTherm and ProNIT: thermodynamic databases for proteins and protein-nucleic acid interactions.

Authors:  M D Shaji Kumar; K Abdulla Bava; M Michael Gromiha; Ponraj Prabakaran; Koji Kitajima; Hatsuho Uedaira; Akinori Sarai
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

8.  BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities.

Authors:  Tiqing Liu; Yuhmei Lin; Xin Wen; Robert N Jorissen; Michael K Gilson
Journal:  Nucleic Acids Res       Date:  2006-12-01       Impact factor: 16.971

9.  Binding MOAD, a high-quality protein-ligand database.

Authors:  Mark L Benson; Richard D Smith; Nickolay A Khazanov; Brandon Dimcheff; John Beaver; Peter Dresslar; Jason Nerothin; Heather A Carlson
Journal:  Nucleic Acids Res       Date:  2007-11-30       Impact factor: 16.971

10.  Tuberculosis drug resistance mutation database.

Authors:  Andreas Sandgren; Michael Strong; Preetika Muthukrishnan; Brian K Weiner; George M Church; Megan B Murray
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069

View more
  38 in total

1.  mCSM-PPI2: predicting the effects of mutations on protein-protein interactions.

Authors:  Carlos H M Rodrigues; Yoochan Myung; Douglas E V Pires; David B Ascher
Journal:  Nucleic Acids Res       Date:  2019-07-02       Impact factor: 16.971

2.  Prediction of impacts of mutations on protein structure and interactions: SDM, a statistical approach, and mCSM, using machine learning.

Authors:  Arun Prasad Pandurangan; Tom L Blundell
Journal:  Protein Sci       Date:  2019-11-25       Impact factor: 6.725

3.  Protein-Ligand Scoring with Convolutional Neural Networks.

Authors:  Matthew Ragoza; Joshua Hochuli; Elisa Idrobo; Jocelyn Sunseri; David Ryan Koes
Journal:  J Chem Inf Model       Date:  2017-04-11       Impact factor: 4.956

4.  mmCSM-AB: guiding rational antibody engineering through multiple point mutations.

Authors:  Yoochan Myung; Douglas E V Pires; David B Ascher
Journal:  Nucleic Acids Res       Date:  2020-07-02       Impact factor: 16.971

5.  SDM: a server for predicting effects of mutations on protein stability.

Authors:  Arun Prasad Pandurangan; Bernardo Ochoa-Montaño; David B Ascher; Tom L Blundell
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

6.  Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Authors:  Yumi Park; Angela Pacitto; Tracy Bayliss; Laura A T Cleghorn; Zhe Wang; Travis Hartman; Kriti Arora; Thomas R Ioerger; Jim Sacchettini; Menico Rizzi; Stefano Donini; Tom L Blundell; David B Ascher; Kyu Rhee; Ardala Breda; Nian Zhou; Veronique Dartois; Surendranadha Reddy Jonnala; Laura E Via; Valerie Mizrahi; Ola Epemolu; Laste Stojanovski; Fred Simeons; Maria Osuna-Cabello; Lucy Ellis; Claire J MacKenzie; Alasdair R C Smith; Susan H Davis; Dinakaran Murugesan; Kirsteen I Buchanan; Penelope A Turner; Margaret Huggett; Fabio Zuccotto; Maria Jose Rebollo-Lopez; Maria Jose Lafuente-Monasterio; Olalla Sanz; Gracia Santos Diaz; Joël Lelièvre; Lluis Ballell; Carolyn Selenski; Matthew Axtman; Sonja Ghidelli-Disse; Hannah Pflaumer; Markus Bösche; Gerard Drewes; Gail M Freiberg; Matthew D Kurnick; Myron Srikumaran; Dale J Kempf; Simon R Green; Peter C Ray; Kevin Read; Paul Wyatt; Clifton E Barry; Helena I Boshoff
Journal:  ACS Infect Dis       Date:  2016-10-17       Impact factor: 5.084

7.  mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures.

Authors:  Douglas E V Pires; David B Ascher
Journal:  Nucleic Acids Res       Date:  2016-05-23       Impact factor: 16.971

8.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures.

Authors:  Douglas E V Pires; Tom L Blundell; David B Ascher
Journal:  J Med Chem       Date:  2015-04-22       Impact factor: 7.446

9.  Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.

Authors:  Ana Carolina Rios Silvino; Gabriel Luiz Costa; Flávia Carolina Faustino de Araújo; David Benjamin Ascher; Douglas Eduardo Valente Pires; Cor Jesus Fernandes Fontes; Luzia Helena Carvalho; Cristiana Ferreira Alves de Brito; Tais Nobrega Sousa
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity.

Authors:  Douglas E V Pires; Jing Chen; Tom L Blundell; David B Ascher
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.